Global Biomarkers and Proteomics Markets Forecast Strong Growth Through 2034

Fortune Business Insights estimates the global biomarkers market was worth about USD 86.9 billion in 2025 and is projected to reach roughly USD 244 billion by 2034, expanding at a compound annual growth rate of 12.1%. North America accounted for the largest share in 2025, contributing 36.9% of market revenue. The report highlights ongoing product launches, strategic partnerships and M&A activity among leading firms such as F. Hoffmann‑La Roche, Abbott, Thermo Fisher Scientific, Bio‑Rad Laboratories and others.

Separately, the proteomics market is expected to grow from USD 39.8 billion in 2026 to about USD 67.6 billion by 2031, a CAGR of 11.1%. Growth is driven by rising demand for protein‑level data in precision medicine, biomarker discovery and drug development. Key players shaping the sector include Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, Danaher, Shimadzu, Waters, Bio‑Rad Laboratories, Bruker, Revvity and Illumina. Both markets are being propelled by advances in life‑science technologies and increasing adoption of personalized therapeutic approaches.